Erythropoietin and Autologous Blood Donation

Maeda, Hitoshi; Hitomi, Yuko; Hirata, Ranko; Tohyama, Hiroshi; Suwata, Junji; Tsuzuki, Nobuyoshi; Shindo, Hiroyuki

doi:10.1016/s0140-6736(89)90478-9

Cited by 36 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal hematological condition (OHC) is defined as the 97th centile for Hb concentration and Ht (corrected for age and sex), which means Hb around 13 g/dl and Ht 35%. Since at 4-6 months of age, the age suggested for surgical treatment according to the concentration of fetal and adult hemoglobin, some children may present with some degree of anemia, 100-200 IU of recombinant human erythropoietin (RHE) may be administered [1,7,39,43,59], together with iron [6], to selected patients twice a week for 2-3 weeks before the actual start of the ATS procedures. RHE is administered according to the response of the given child and repeated in cases of inadequate response.…”

Section: Hemoglobin and Hematocritmentioning

confidence: 99%

"No Allogeneic Blood Transfusion" protocol for the surgical correction of craniosynostoses

Velardi

Chirico

Rocco

et al. 1998

Child's Nervous System

View full text Add to dashboard Cite

Improved anesthesiological and surgical care has resulted in a progressively declining need for allogeneic blood transfusion. In infants with craniosynostosis, however, allogeneic blood transfusion is still performed as a routine procedure. In the present paper, the authors describe a protocol they have devised with the aim of limiting or even avoiding allogeneic blood transfusion even in very young patients, consequently avoiding the risks of infective or immunologic reactions associated with the procedure. The protocol is based on stimulation of the hematopoietic system with erythropoietin, selection of an appropriate age for operation when a favorable balance between fetal and adult-type hemoglobin is established (that is after 4-6 months), preoperative preparation of the autologous blood supply, and intraoperative blood salvage.

show abstract

Section: Hemoglobin and Hematocritmentioning

confidence: 99%

"No Allogeneic Blood Transfusion" protocol for the surgical correction of craniosynostoses

Velardi

Chirico

Rocco

et al. 1998

Child's Nervous System

View full text Add to dashboard Cite

show abstract

“…194 Maeda et al administered erythropoietin (6000 U IV) to autologous donors three times per week over a 24-day period prior to their scheduled orthopedic surgery. 195 Autologous blood was then collected on preoperative days 17, 10, and 3. It was found that by the third donation, hemoglobin was significantly higher in the erythropoietin treated subjects (12.7 vs 10.7), and that while 40% of the non-erythropoietin treated individu-als required homologous blood, none of the erythropoietin group did.…”

Section: Autologous Blood Donationmentioning

confidence: 99%

Erythropoietin in Cardiac Surgery

et al. 1993

View full text Add to dashboard Cite

Erythropoietin is the primary growth factor for red blood cells. A glycoprotein hormone synthesized by the kidneys, erythropoietin serves to increase red blood cell production in response to tissue hypoxia. It exerts its effect by increasing the numbers of erythroid progenitor cells in the bone marrow, and by increasing the rate at which their development is accomplished. With the introduction of recombinant erythropoietin in 1987, an important pharmacological agent became available for the manipulation of erythropoiesis. While used primarily for the treatment of the anemia of renal failure, recombinant erythropoietin has also shown usefulness in treating other types of anemias in which the endogenous erythropoietin response is insufficient. Perioperative use of the drug grew as a natural extension of this, and erythropoietin has been applied to correct preoperative anemia, augment autologous blood donation, and improve postoperative red cell recovery. Analysis of these perioperative clinical studies reveals success in these areas, but it also reveals that closer attention to the physiology of the natural response, and to the pharmacology of the recombinant product, might significantly improve results. Such an improvement in efficacy is both desirable and necessary when use of the drug is viewed in the setting of today's changing health care environment. By optimizing dosing schedules and targeting the drug to those most at risk for red cell transfusion, recombinant erythropoietin will likely become an important tool in efforts to achieve the elusive goal of bloodless cardiac surgery.

show abstract

“…The results of preliminary studies designed to clar ify the actual role of rHuEpo treatment in this clinical setting have recently been published [71,72]. About 40% more red cells could be collected from patients receiving rHuEpo than from the placebo-treated group, and the requirement for homologous blood was consequently less; no adverse effects related to rHuEpo administration were observed.…”

Section: Autotransfusion In Surgical Settingsmentioning

confidence: 99%

Erythropoietin: Clinical Applications

Foa¹

1991

Acta Haematol

View full text Add to dashboard Cite

The last few years have seen an enormous increase in our knowledge on the haematopoietic growth factor erythropoietin (Epo), firstly with its purification and determination of its primary amino acid sequence, and more recently with the isolation of the Epo gene and its expression in mammalian cell lines. This review article summarizes the crucial biological features of Epo and critically examines the main results obtained in clinical trials on humans.

show abstract

Erythropoietin and Autologous Blood Donation

Cited by 36 publications

References 0 publications

"No Allogeneic Blood Transfusion" protocol for the surgical correction of craniosynostoses

"No Allogeneic Blood Transfusion" protocol for the surgical correction of craniosynostoses

Erythropoietin in Cardiac Surgery

Erythropoietin: Clinical Applications

Contact Info

Product

Resources

About